Search results
Results from the WOW.Com Content Network
In 2013, the Indian Supreme Court issued a decision rejecting Novartis' patent application in India on the final form of Gleevec, Novartis's cancer drug; the case caused great controversy. [45] In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards ...
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
Thomas Ebeling (born February 9, 1959, in Hanover [1]) is a German executive and the former CEO of ProSiebenSat.1 Media and Novartis. Thomas Ebeling studied psychology in Hamburg. After graduating in 1987, [2] he started at Reemtsma. [3] In 1991, he switched to Pepsi-Cola Germany as a Marketing Manager. From 1994, he served as the National ...
Swiss drugmaker Novartis <NOVN.S> has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently ...
Novartis AG (NYSE: NVS) has appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down after seven years ...
He started his career in 1982 with Sandoz, who merged with Ciba-Geigy in 1996 to form Novartis. [4] At Sandoz, he worked in research and development and became head of development in 1994. Following the merger into Novartis, Reinhardt was responsible for preclinical development throughout the group and later for the entire drug development.
Novartis (NVS) progresses with its MS candidate, siponimod, as both the FDA and the EMA accepts the applications for the drug.
Paul Herrling is the head of corporate research at Novartis and the chairman of board of the Novartis Institute for Tropical Diseases, Singapore [1] since 2002. [2] Prior to this, he was the head of Global Research of Novartis Pharma.